Werner syndrome is genetically linked to mutations in WRN that encodes a DNA helicase-nuclease believed to operate at stalled replication forks. Using a newly identified small-molecule inhibitor of WRN helicase (NSC 617145), we investigated the role of WRN in the interstrand cross-link (ICL) response in cells derived from patients with Fanconi anemia, a hereditary disorder characterized by bone marrow failure and cancer. In FA-D2
Introduction
Werner syndrome, characterized by premature aging and cancer predisposition (1) , is caused by autosomal recessive mutations in WRN (2), encoding a RecQ DNA helicase-nuclease implicated in genomic stability (3, 4) . WRN helicase can unwind key homologous recombination DNA intermediates and interacts with proteins implicated in DNA replication, recombinational repair, and telomere maintenance (5) . Werner syndrome cells are sensitive to certain DNA-damaging agents, and display defects in resolution of recombination intermediates and a prolonged S-phase (6) . WRN is required for normal replication fork progression after DNA damage or fork arrest (7) .
Werner syndrome cells are sensitive to interstrand crosslink (ICL)-inducing agents (8) and undergo apoptosis in Sphase (9) . Cellular studies suggest WRN helicase, in conjunction with BRCA1, is required to process DNA ICLs (10) . WRN is required for ataxia-telangiectasia mutated (ATM) activation and the intra-S-phase checkpoint in response to ICL-induced double-strand breaks (DSB; ref. 11), suggesting WRN and ATM collaborate in response to collapsed forks at ICL-induced DSBs. Biochemical studies using a reconstituted system with a DNA substrate harboring a psoralen ICL suggested that WRN helicase is required for ICL processing (12) .
Patients with Fanconi anemia suffer from progressive bone marrow failure and cancer predisposition, and their cells (such as Werner syndrome cells) are sensitive to ICL agents, only to a greater extent (13) . In fact, a chromosome breakage test using Fanconi anemia patient cells exposed to an ICL-inducing agent is used as a primary diagnostic tool for Fanconi anemia (14) . The Fanconi anemia pathway is involved in initial recognition and unhooking of an ICL and subsequent repair of the ICLinduced DSB in conjunction with homologous recombination or translesion synthesis pathways, but the detailed molecular mechanism is an active area of investigation (15) . One function of the Fanconi anemia pathway is to channel DSBs through the homologous recombination pathway, thereby preventing inappropriate engagement of breaks by error-prone nonhomologous end-joining (NHEJ; refs. 16, 17) . However, the relationship between DNA repair pathways is complex, as evidenced by a recent mouse study showing that deletion of 53BP1 or Ku exacerbates genomic instability in FANCD2-deficient cells (18) .
To understand the role of WRN in the ICL response, we examined effects of a small-molecule WRN helicase inhibitor in a Fanconi anemia-mutant genetic background. A more potent structural analog of the previously identified parent compound NSC 19630 (19) was discovered that is blocked from potential thiol reactivity but retains the ability to modulate WRN function in vivo. The WRN helicase inhibitor NSC 617145 acted synergistically with a very limited concentration of mitomycin C to induce DSB accumulation and chromosomal abnormalities, and activate the DNA damage response in Fanconi anemia-mutant cells. NSC 617145 exposure resulted in enhanced accumulation of DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) pS2056 foci and Rad51 foci in mitomycin C-treated Fanconi anemia-deficient cells, suggesting that WRN helicase inhibition prevents processing of Rad51-mediated recombination products and activates NHEJ. WRN helicase may be a suitable target for chemotherapy strategies in Fanconi anemia-deficient tumors.
Materials and Methods

Cell lines and culture
HeLa (CCL-2), U2OS (HTB96), and HCT116 (CCL-247) cell lines were obtained from American Type Culture Collection where they were tested and authenticated. HCT116 p53 double knockout cells were obtained from the laboratory of Dr. B. Vogelstein (Johns Hopkins University, Baltimore, MD) where they were tested and authenticated (20) . All these cell lines were grown in Dulbecco's Modified Eagle Medium supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% Lglutamine at 37 C in 5% CO 2 . PSNF5 [Bloom syndrome (BLM)-corrected] and PSNG13 (BLM-mutant) are isogenic cell lines that were obtained from the laboratory of Dr. I. Hickson (University of Copenhagen, Copenhagen, Denmark) where they were tested and authenticated (21, 22) . PSNF5 is a stable BLM cell line expressing a FLAG epitope-tagged, wildtype BLM protein from the cytomegalovirus (CMV) promoter in a pcDNA3-based construct. PSNG13 is a control BLM cell transfectant containing the pcDNA3 vector only. The BLMmutant and -corrected cell lines were grown in the same media as HeLa cells but supplemented with 350 mg/mL G418. The simian virus 40-transformed Fanconi anemia-mutant fibroblasts, PD20 (FA-D2), GM6914 (FA-A), and their respective corrected counterparts were provided by Fanconi Anemia Cell Repository at Oregon Health & Science University (Portland, OR) where they were tested and authenticated. Fanconi anemia-mutant and -corrected cells were grown in the same medium as HeLa cells but supplemented with 0.2 mg/mL puromycin.
Cell proliferation assays
Proliferation was measured using WST-1 assay (Roche) as described previously (19) . and/or CG: 5 0 -GUGUAUAGUUACGAUGCUAGUGAUU-3 0 ) and control siRNA (19) were transfected using Lipofectamine 2000 as per the manufacturer's protocol (Invitrogen). Cells were plated to 50% to 60% confluence in 10-cm dishes 24 hours before transfection. siRNA (0.6 nmol) was mixed with 30 mL of Lipofectamine 2000 in 3 mL of Opti-MEM (Invitrogen). The mixture was added to cells that were subsequently incubated for 6 hours. After 24 hours, a second transfection was carried out similarly. Seventy-two hours after the initial transfection, cells were harvested for preparing lysate or treated with smallmolecule compounds or dimethyl sulfoxide (DMSO) at the indicated concentrations and cell proliferation was measured using WST-1 reagent (Roche) as described for HeLa cells. For Fanconi anemia-mutant cells, siRNA transfection and treatment with NSC 617145 was carried out as described previously except that OD 450 was measured after 48 hours of treatment with mitomycin C and/or NSC 617145.
For lysate preparation, cells were washed twice with 1Â PBS. Radioimmunoprecipitation assay (RIPA) buffer [10 mmol/L sodium phosphate (pH 7.2), 300 mmol/L NaCl, 0.1% SDS, 1% NP-40, 1% sodium deoxycholate, and 2 mmol/L EDTA] was added to the cells and the cells were incubated at 4 C for 30 minutes. Cells were scraped and the suspension was further incubated on ice for 30 minutes. Cell suspension was centrifuged at 18,500 Â g for 10 minutes at 4 C and supernatant was collected. Twenty microgram of the lysate was loaded on 8% to 16% SDS-PAGE. Protein was transferred onto a polyvinylidene difluoride (PVDF) membrane and blot was probed with anti-WRN mouse monoclonal antibody (1:1,000; Spring Valley Laboratories). For secondary antibody, peroxidase-conjugated anti-mouse immunoglobulin G (IgG; 1:1,000; Vector Laboratories) was used. Blot was developed using ECL Plus Western Blot Detection Kit as per the manufacturer's protocol (Amersham). As a loading control, blot was stripped and then reprobed with anti-actin antibody (1:5,000; Sigma).
Analysis of metaphase chromosomes
Cell harvest and metaphase slide preparation was carried out for metaphase analysis as described previously (23) .
See Supplementary Data for additional information.
Results
Inhibition of WRN helicase activity by small-molecule NSC 617145
To identify small molecules that inhibit WRN helicase activity in a more potent manner than the previously identified compound NSC 19630 (19), we selected four close structural analogs and three compounds whose pattern of activity in the NCI60 screen matched NSC 19630 for analysis ( Supplementary  Fig. S1 ). One of the latter compounds, NSC 617145, is also a structural analog, but blocked with respect to thiol reactivity in the five-membered rings by Cl atoms. NSC 617145 inhibited WRN helicase activity in a concentration-dependent manner in vitro ( Supplementary Fig. S2A ), yielding an IC 50 value of 230 nmol/L. NSC 617145 inhibited WRN ATPase in a dose-dependent manner (Supplementary Fig. S2B ). No detectable effect on WRN exonuclease was observed ( Supplementary Fig. S2C ).
To examine specificity of WRN helicase inhibition, we tested 5 mmol/L NSC 617145 ($20-fold >IC 50 value) on DNA unwinding catalyzed by various helicases. No significant inhibition of unwinding was observed with BLM, FANCJ, ChlR1, RecQ, and UvrD, and only a very modest (7%) inhibition of RECQ1 ( Supplementary Fig. S2D ) was observed.
To determine their potency in vivo, HeLa cells were exposed to increasing concentrations of selected analogs or DMSO for 0 to 3 days. Of the selected analogs, NSC 617145 showed maximal inhibition of proliferation (98%) at the lowest concentration of NSC 617145 (1.5 mmol/L; Fig. 1A ; Supplementary Fig. S3 ). To address whether the effect was cytostatic or cytotoxic, HeLa cells were exposed to NSC 617145 for 3 days, replenished with media lacking NSC 617145, and allowed to recover for 0 to 3 days (Fig. 1B) . The lack of recovery from NSC 617145 suggested a cytotoxic effect. To determine whether the effect of NSC 617145 was WRN-dependent, we compared its effect on HeLa cells depleted of WRN (!90%) with NS-siRNAtransfected cells. WRN-depleted cells grown in the presence of 1.5 mmol/L NSC 617145 were resistant to its antiproliferative effects, whereas NS-siRNA HeLa cells were highly sensitive to NSC 617145 (Fig. 1C) . These results were confirmed by 2 different WRN-siRNA molecules that independently conferred resistance to NSC 617145 ( Supplementary  Fig. S4 ). Western blot analyses showed that WRN depletion by either WRN-siRNA or combination was more than 90% ( Supplementary Fig. S4 ).
NSC 617145 may exert its effect through a mechanism in which the NSC 617145-inhibited WRN helicase induces greater damage by interfering with a compensatory mechanism(s). To determine whether the effect of NSC 617145 is dependent on a helicase-active version of WRN, HeLa cells were depleted of endogenous WRN, and siRNA-resistant WRN [wild-type or helicase inactive K577M (24)] was expressed. The resulting cells were tested for sensitivity to NSC 617145. It was observed that the WRN-depleted cells rescued with wild-type WRN were sensitive to the WRN helicase inhibitor compared with empty vector-transfected cells, supporting the finding that the inhibition of cell proliferation by NSC 617145 is WRN-dependent ( Supplementary Fig. S5 ). However, WRN-depleted cells expressing the helicase-inactive WRN-K577M behaved similar to the WRN-depleted cells transfected with empty vector, suggesting that they were resistant to the negative effect of WRN helicase inhibitor NSC 617145 on cell viability.
Because NSC 617145 inhibited proliferation of p53-inactivated HeLa cells, we examined its effect on proliferation of U2OS cells with wild-type p53. NSC 617145 (1.5 mmol/L) inhibited U2OS proliferation by 80% after day 2 (Supplementary Fig. S6A ), suggesting that the effect of NSC 617145 was not dependent on p53 status. We also tested a pair of isogenic p53-negative and -positive HCT116 cells for sensitivity to NSC 617145 (1.5 mmol/L). Both cell lines were sensitive to the compound; however, p53-deficient cells were 2-fold more resistant than p53-proficient cells (Supplementary Fig. S6B ). Because NSC 617145 exerted a WRN-dependent effect on proliferation, we evaluated whether cells mutated for the sequence-related BLM helicase were sensitive. BLM-null and -corrected cells displayed similar sensitivity to NSC 617145 ( Supplementary Fig. S6C ), suggesting BLM does not play a role. 
NSC 617145 induces WRN binding to chromatin and proteasomal degradation
We reasoned that NSC 617145 might target cellular WRN for helicase inhibition and induce toxic DNA lesions mediated by WRN's interaction with genomic DNA, prompting us to ask whether poisoned WRN became enriched in the chromatin fraction. Western blot analysis of nuclear soluble and chromatin-bound fractions prepared from HeLa cells exposed to NSC 617145 showed a dose-dependent increase in WRN bound to chromatin (Fig. 2A) . We also observed that the amount of WRN from extract of HeLa cells exposed to NSC 617145 (0.75 mmol/L) for 6 hours was reduced compared with DMSOtreated cells (Fig. 2B) . Inclusion of proteasome inhibitor MG132 restored WRN level to that of DMSO-treated cells (Fig.  2B) . Thus, NSC 617145 causes WRN to become degraded by a proteasome-mediated pathway. Consistent with reduction of WRN protein in NSC 617145-treated cells, helicase activity catalyzed by immunoprecipitated WRN from an equivalent amount of total extract protein from HeLa cells treated with NSC 617145 (0.75 mmol/L; 4 hours) was reduced 4-fold compared with helicase activity by immunoprecipitated WRN from DMSO-treated cells (Fig. 2C ).
Synergistic effect of NSC 617145 and DNA cross-linking agent mitomycin C on cell proliferation
We sought to use the newly identified WRN helicase inhibitor as a tool to explore whether WRN helicase activity helps cells cope with stress imposed by the DNA cross-linking agent mitomycin C. Treatment with either NSC 617145 (0.5 mmol/L) or mitomycin C (9.4 nmol/L) exerted no significant effect on proliferation. However, cotreatment with both NSC 617145 (0.5 mmol/L) and mitomycin C (9.4 nmol/L) resulted in a 45% reduction in proliferation (Fig. 3A) . In contrast, treatment with NSC 617145 (0.5 mmol/L) and hydroxyurea (0-5 mmol/L) had a similar effect on proliferation compared with hydroxyurea alone (Supplementary Fig. S11A ), suggesting that the apparent synergism between NSC 617145 and mitomycin C is not a general effect imposed by other forms of replicative stress such as hydroxyurea that depletes the nucleotide pool.
NSC 617145-treated Fanconi anemia-mutant cells are hypersensitive to mitomycin C On the basis of the synergistic effect of NSC 617145 and mitomycin C, we hypothesized that WRN might participate in a pathway that is partially redundant with Fanconi anemia-mediated ICL repair. For this, we examined sensitivity of FA-D2-mutant and -corrected cells to mitomycin C and NSC 617145. Dose-response curves for mitomycin C and NSC 617145 sensitivity of FA-D2 cells indicated drug concentrations at which only modest effects on proliferation were observed ( Supplementary Fig. S11B and S11C). NSC 617145 (0.125 mmol/L) or mitomycin C (9.4 nmol/L) exerted only a mild effect on cell proliferation; however, a significant 45% reduction was observed for cells treated with both NSC 617145 and mitomycin C (Fig. 3B) . In contrast, FA-D2 þ/þ cells showed only a 10% reduction of proliferation by combined treatment of NSC 617145 and mitomycin C (Fig. 3B) .
Sensitization of FA-D2
À/À cells to mitomycin C by WRN helicase inhibition is distinct from the effect imposed by a deficiency or inhibition of proteins in the NHEJ pathway (LIG-4 and Ku-70), which suppress ICL-sensitivity of Fanconi anemia-deficient cells (16, 17) . Combinatorial treatment of FA-A À/À cells with NSC 617145
(0.125 mmol/L) and mitomycin C (9.4 nmol/L) resulted in 60% reduction in proliferation compared with very modest effects exerted by either agent alone (Fig. 3C) . Moreover, the effect was dependent on FANCA status as only 10% reduction in proliferation was observed for FA-A þ/þ cells exposed to both (Fig. 3D) , whereas NS-siRNA FA-D2 À/À cells were sensitive to cotreatment with NSC 617145 and mitomycin C, as evidenced by 40% reduction in proliferation (Fig. 3E) . In contrast, no difference in proliferation was observed with WRN-depleted or NS-siRNA-treated FA-D2 þ/þ cells cotreated with these NSC 617145 and mitomycin C concentrations ( Fig. 3D and E). Furthermore, WRN depletion in FA-D2 À/À cells did not affect mitomycin C sensitivity as compared with NS-siRNAtreated or untransfected cells ( Supplementary Fig. S12 ), suggesting WRN helicase inhibition by NSC 617145 interfered with the ability of FA-D2 À/À cells to cope with mitomycin Cinduced DNA damage.
NSC 617145 and mitomycin C act synergistically to induce DNA damage and activate ATM Failure to repair DNA ICLs in dividing cells would be expected to result in blocked replication forks and hence DSBs. Cotreatment of FA-D2
À/À cells with NSC 617145 (0.125 mmol/L) and mitomycin C (9.4 nmol/L) resulted in a substantial increase in percentage (80%) of cells with more than 15 g-H2AX foci (Fig. 4A) . In contrast, only 30% FA-D2
þ/þ cells exposed to NSC 617145 and mitomycin C showed more than 15 g-H2AX foci (Fig. 4B) . The difference in sensitivity of FA-D2 À/À versus FA-D2 þ/þ cells exposed to very low concentrations of either mitomycin C or WRN inhibitor was modest (NSC 617145) or hardly apparent (mitomycin C) compared þ/þ cells (Fig. 5A ).
FA-D2
À/À cells exposed to very low dose of NSC 617145 (0.125 mmol/L) and mitomycin C (9.4 nmol/L) retained high levels of pATM-Ser1981 even after 24-hour exposure (data not shown), suggesting a significant delay in damage repair when WRN helicase was inhibited. Thus, NSC 617145 and mitomycin C act synergistically to induce DNA damage and activate ATM. Fig. 6A and B) . In contrast, only 15% of FA-D2 þ/þ cells exposed to NSC 617145 and mitomycin C showed more than 15 DNA-PKcs pS2056 foci ( Fig. 6A and B) . The difference in sensitivity between FA-D2 À/À and FA-D2 increased chromosomal instability due to more DSBs repaired by the error-prone pathway. Strikingly, FA-D2 þ/þ cells cotreated with mitomycin C (9.4 nmol/L) and NSC 617145 (0.125 mmol/L) showed similar levels of DNA-PKcs pS2056 foci as individually treated or DMSO control cells ( Fig. 6A and B) , suggesting an important role for WRN helicase in processing of mitomycin C-induced cross-links converted to DSBs when the Fanconi anemia pathway is defective. Fig. 7A  and B) . Collectively, these results suggest that mitomycin C-induced DNA cross-links in FA-D2 À/À cells exposed to WRN helicase inhibitor are converted to DSBs and the homologous recombination pathway is activated but homologous recombination intermediates fail to be subsequently resolved.
Discussion
In this study, we discovered a new inhibitor of WRN helicase activity (NSC 617145) that negatively affects cell proliferation and induces DNA damage in a WRN-dependent manner. normal cellular DNA metabolism. The synergistic effect of NSC 617145 and mitomycin C was not observed for hydroxyurea, suggesting that impairment of WRN helicase activity exacerbates the effect of mitomycin C-induced DNA damage during replication but not an effect exerted by an agent (hydroxyurea) that primarily induces replication stress. We used the WRN helicase inhibitor to sensitize a Fanconi anemia-mutant because mounting evidence points toward a pivotal role of the Fanconi anemia pathway to coordinate a robust ICL response when WRN is also likely to act. WRN helicase inhibition by NSC 617145 makes FA-A or FA-D2 cells highly sensitive to very low mitomycin C concentrations that would otherwise be only marginally active in normal cells. Furthermore, the effect of combined mitomycin C/NSC 617145 treatment is a consequence of a Fanconi anemia pathway deficiency rather than a defect in a specific Fanconi anemia gene.
The synergistic effect of NSC 617145 and mitomycin C in the FA-D2-mutant was apparent by robust g-H2AX staining, ATM activation, and increased chromosomal abnormalities. Moreover, accumulation of DNA-PKcs pS2056 foci suggests that FA-D2 cells attempted to deal with mitomycin C-induced DSBs by error-prone NHEJ when WRN helicase was pharmacologically inhibited. This finding builds on previous evidence that the Fanconi anemia pathway plays an important role in preventing aberrant NHEJ-mediated repair (16, 17) , and implicates a role of WRN helicase in repair pathway choice. In addition to its helicase-dependent role in recombinational repair, WRN may have a structural role to enable repair of mitomycin C-induced DNA damage. This would be akin to the observation that a WRN helicase/exonuclease double-mutant complemented the NHEJ defect of WRN À/À cells (30) . Although experimental data suggest that WRN participates in an alternative NHEJ repair pathway of DSBs induced by increased reactive oxygen species in chronic myeloid leukemia cells (31) , it is unclear whether this pathway is relevant to a role of WRN helicase to confer mitomycin C resistance in Fanconi anemiadeficient fibroblasts. Further studies will be necessary to evaluate whether an alternate end-joining pathway or homologous recombination is important for repair of mitomycin C-induced lesions in the WRN helicase-inhibited condition. We also observed Rad51 foci accumulation in FA-D2
À/À cells cotreated with mitomycin C and NSC 617145, suggesting that homologous recombination was activated and at least some DSBs were channeled into homology-mediated repair. However, as WRN plays a role in resolution of homologous recombination intermediates (6), NSC 617145 inhibition of WRN helicase activity might lead to accumulation of homologous recombination structures. We observed phosphorylation of DNA-PKcs only under conditions of WRN helicase inhibition in FA-D2 À/À cells, suggesting that NHEJ was elicited;
however, the mechanism of DNA-PKcs recruitment is still unclear. Development of helicase inhibitors such as NSC 617145 that possess chemical stability and lack of nonspecific reactivity to thiol and other functional groups may prove useful for study of compensatory DNA repair pathways dependent on DNA unwinding by WRN or related helicases. In addition to their use as research tools, small-molecular inhibitors of WRN and other helicases may be useful for development of anticancer strategies that rely on synthetic lethality for targeting tumors with preexisting DNA repair deficiencies (32) .
Demonstration that very low concentrations of the chemotherapy drug mitomycin C are cytotoxic for Fanconi anemia-mutant cells exposed to the helicase inhibitor may have implications for strategies that target Fanconi anemia DNA repair pathway-deficient tumors. Certain sporadic head and neck, lung, ovarian, cervical, and hematologic cancers are characterized by epigenetic silencing of wildtype Fanconi anemia gene expression (33) . It is estimated that 15% of all cancers harbor defects in the Fanconi anemia pathway (34) . A significant number of these tumors may become reliant on WRN or other helicases to deal with DNA damage such as strand breaks. WRN may be a suitable target for pharmacologic inhibition to sensitize Fanconi anemiadeficient tumors to chemotherapy drugs such as DNA crosslinkers.
In addition to epigenetic silencing, LOH from an additional mutation in an Fanconi anemia gene in heterozygous carriers may lead to increased cancer risk later in life (33, 35) . Fanconi anemia pathway-deficient fibroblasts were found to be highly sensitive to silencing of ATM kinase (33) . FANCG-and FANCCdeficient pancreatic tumor lines were sensitive to a pharmacologic inhibitor of ATM, raising the possibility for an anticancer treatment. More recently, Fanconi anemia-deficient cell lines were shown to be hypersensitive to inhibition of CHK1 kinase either by siRNA or a pharmacologic inhibitor of CHK1 kinase activity (36) . Unlike the hypersensitivity of Fanconi anemia-deficient cells to CHK1 silencing or kinase inhibition, WRN depletion did not increase sensitivity of FA-D2 À/À cells to mitomycin C. This suggests that NSC 617145 exerted its effect through a dominant-negative mechanism in which NSC 617145-inhibited WRN helicase induced greater damage by blocking compensatory mechanism(s). Inhibition of WRN or a related helicase by a small molecule may provide an alternative strategy for targeting Fanconi anemia-deficient tumors that is unique from approaches such as targeting the CHK1 or ATM kinase response.
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